Clovis Oncology announces positive outcome in European opposition proceeding related to Rubraca

Clovis Oncology announces positive outcome in European opposition proceeding related to Rubraca

Tuesday, December 04, 2018

The process involves latching on and breaking down of enzymes viagra prices in usa (turn off), thereby making the effect long period. The parent chemical sildenafil citrate is a very potential form of cheap viagra cialis, that s formulated as the basic function for treating erectile problems in men. No doubt that age plays a very important role in the love life of males. sildenafil without prescription LifeSkills4Kids is dedicated and committed to offering evidence based and proven solutions pharmacy viagra for children and adults.

Clovis Oncology, Inc. announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153 in amended form covering certain crystalline forms of rucaparib camsylate, including rucaparib S-camsylate Form A, the crystalline form in Rubraca.

In its oral decision announced at the hearing, the Opposition Division upheld claims, narrowed from the originally granted patent, to certain crystalline forms of rucaparib camsylate. These forms include, but are not limited to, the commercial product.

The European Opposition Division found patentability of the claimed forms based on the inventiveness of these crystalline forms and a constellation of unexpected properties. The European patent was opposed by two opponents.

Clovis and/or either opponent have an opportunity to appeal the decision of the European Opposition Division within two months of the written decision, which is expected in the next few months. If appealed, all claims in the originally granted patent will remain in force until the Technical Board of Appeal issues its decision. In addition to the rucaparib camsylate patent protection through at least 2031 confirmed today, the commercial form of Rubraca is also entitled to European regulatory exclusivity until at least 2028 (and 2029 if an indication in a second tumor type is approved).

Also, Clovis has filed for supplementary protection certificate (SPC) extension on this rucaparib camsylate patent in various European countries, which if approved, would provide extension of protection until 2033 under this patent. “We are very pleased with the outcome of the opposition proceedings today, but more importantly, we are gratified that the European Patent Office acknowledged the innovation behind this invention and upheld robust patent protection for Rubraca in Europe,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.

“This patent represents an important component of the intellectual property for Rubraca and we are happy that the Opposition Division upheld the relevant claims of the patent that cover the commercial form of Rubraca as well as other forms of rucaparib camsylate. We look forward to commercializing Rubraca in Europe and with this outcome, we are well-positioned to do so for a very long time.”

About Rubraca ® (rucaparib) Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. and Europe.

Key Facts
    •  News CategoryIntellectual Property
      Other Product News
      Product Development
    •  CompanyClovis Oncology Inc
    •  CountryEurope > Netherlands
      North America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

1 + 4 =